| A comprehensive review on MAPK: a promising therapeutic target in cancer C Braicu, M Buse, C Busuioc, R Drula, D Gulei, L Raduly, A Rusu, A Irimie, ... Cancers 11 (10), 1618, 2019 | 863 | 2019 |
| MicroRNAs from liquid biopsy derived extracellular vesicles: recent advances in detection and characterization methods R Drula, LF Ott, I Berindan-Neagoe, K Pantel, GA Calin Cancers 12 (8), 2009, 2020 | 54 | 2020 |
| Critical function of circular RNAs in lung cancer R Drula, C Braicu, A Harangus, SM Nabavi, M Trif, O Slaby, C Ionescu, ... Wiley Interdisciplinary Reviews: RNA 11 (5), e1592, 2020 | 39 | 2020 |
| Current concepts of non-coding RNAs in the pathogenesis of non-clear cell renal cell carcinoma DA Barth, O Slaby, C Klec, J Juracek, R Drula, GA Calin, M Pichler Cancers 11 (10), 1580, 2019 | 38 | 2019 |
| The roles of the colon cancer associated transcript 2 (CCAT2) long non-coding RNA in cancer: a comprehensive characterization of the tumorigenic and molecular functions R Pirlog, R Drula, A Nutu, GA Calin, I Berindan-Neagoe International journal of molecular sciences 22 (22), 12491, 2021 | 30 | 2021 |
| Circulating non-coding RNAs in renal cell carcinoma—pathogenesis and potential implications as clinical biomarkers DA Barth, R Drula, L Ott, L Fabris, O Slaby, GA Calin, M Pichler Frontiers in Cell and Developmental Biology 8, 828, 2020 | 29 | 2020 |
| 17β-estradiol promotes extracellular vesicle release and selective miRNA loading in ERα-positive breast cancer R Drula, B Pardini, X Fu, MC De los Santos, A Jurj, L Pang, SM El-Daly, ... Proceedings of the National Academy of Sciences 120 (23), e2122053120, 2023 | 17 | 2023 |
| Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML R Drula, S Iluta, D Gulei, C Iuga, D Dima, G Ghiaur, AD Buzoianu, ... Blood Reviews 56, 100971, 2022 | 14 | 2022 |
| Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma D Kegyes, D Gulei, R Drula, D Cenariu, B Tigu, D Dima, A Tanase, ... Blood Reviews 61, 101100, 2023 | 13 | 2023 |
| The tumor suppressor functions of ubiquitin ligase KPC1: from cell-cycle control to NF-κB regulator D Gulei, R Drula, G Ghiaur, AD Buzoianu, Y Kravtsova-Ivantsiv, ... Cancer Research 83 (11), 1762-1767, 2023 | 12 | 2023 |
| Investigating circular RNAs using qRT-PCR; roundup of optimization and processing steps R Drula, C Braicu, S Chira, I Berindan-Neagoe International Journal of Molecular Sciences 24 (6), 5721, 2023 | 11 | 2023 |
| A comprehensive Review on MAPK: a promising therapeutic target in cancer. Cancers 11, 1618 C Braicu, M Buse, C Busuioc, R Drula, D Gulei, L Raduly, A Rusu, A Irimie, ... | 10 | 2019 |
| circFOXO3: Going around the mechanistic networks in cancer by interfering with miRNAs regulatory networks R Drula, R Pirlog, M Trif, O Slaby, C Braicu, I Berindan-Neagoe Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1867 (5), 166045, 2021 | 6 | 2021 |
| microRNA in cancer: An overview R Drula, S Mohapatra, GA Calin MicroRNA in Human Malignancies, 21-28, 2022 | 2 | 2022 |
| RNA sequencing suggests that non‐coding RNAs play a role in the development of acquired haemophilia AB Tigu, I Hotea, R Drula, AA Zimta, N Dirzu, M Santa, C Constantinescu, ... Journal of Cellular and Molecular Medicine 27 (13), 1790-1796, 2023 | 1 | 2023 |
| MicroRNAs: where brilliance, perseverance, and ambition converged R Drula, GA Calin The Journal of Clinical Investigation 135 (2), 2025 | | 2025 |
| 5-Azacytidine treatment inhibits the development of lung cancer models via epigenetic reprogramming and activation of cellular pathways with anti-tumor activity RA Munteanu, CS Moldovan, AB Tigu, R Drula, R Feder, L Magdo, A Jurj, ... Medicine and Pharmacy Reports 97 (4), 488, 2024 | | 2024 |
| Single low‐dose decitabine as frontline therapy of acute myeloid leukaemia, with venetoclax salvage C Jitaru, MC Peters, L Aggarwal, A Bancos, AB Tigu, D Cenariu, ... Journal of Cellular and Molecular Medicine 28 (20), e18592, 2024 | | 2024 |
| RNA methylation sequencing shows different gene expression signatures for response to azacytidine therapy in high‐grade myelodysplastic syndromes D Gulei, V Moisoiu, D Kegyes, R Drula, S Iluta, AB Tigu, M Nistor, C Jitaru, ... Journal of Cellular and Molecular Medicine 28 (18), e70078, 2024 | | 2024 |
| Low-Dose Decitabine Plus Venetoclax As Frontline Treatment of Acute Myeloid Leukemia M Peters, C Jitaru, A Bancos, AB Tigu, D Cenariu, C Selicean, V Moisoiu, ... Transplantation and Cellular Therapy 30 (2), S113-S114, 2024 | | 2024 |